Stock Events

Stock Events

Illumina 

$218.22
508
-$3.44-1.55% 20:00 Today
+$4.58+2.1%22:10After hours

Statistics

Day High
219.58
Day Low
213.95
52W High
231.81
52W Low
88
Volume
1,682,969
Avg. Volume
1,928,801
Mkt Cap
32.95B
P/E Ratio
34.58
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
0.94
1.08
1.22
1.36
Expected EPS
1.357355
Actual EPS
N/A

Financials

19.57%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
4.34BRevenue
850MNet Income

Analyst Ratings

205.75Average Price Target
The highest estimate is 235.00.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
17%
Sell
17%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ILMN. It's not an investment recommendation.
Amazon
114
AMZN
Microsoft
110
MSFT
Tesla
107
TSLA
NVIDIA
105
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pacific Biosciences of California
PACB
Mkt Cap435.16M
Pacific Biosciences offers long-read sequencing technologies that compete with Illumina's short-read sequencing platforms, providing an alternative in genomic sequencing.
Thermo Fisher Scientific
TMO
Mkt Cap230.05B
Thermo Fisher Scientific competes with Illumina in the life sciences and diagnostics market, offering a range of sequencing and genetic analysis products.
Bio-Rad Laboratories
BIO.B
Mkt Cap8.84B
Bio-Rad Laboratories provides a variety of research and clinical diagnostic products that compete with Illumina's offerings in genomic and molecular diagnostics.
Qiagen NV
QGEN
Mkt Cap8.9B
Qiagen competes with Illumina in the provision of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG competes through its acquisition of GenMark Diagnostics and a strong portfolio in diagnostics and genomic sequencing, challenging Illumina's market share.
Agenus
AGEN
Mkt Cap344.77M
Agilent Technologies offers a range of products for genomics and molecular biology that compete with Illumina's sequencing and array technologies.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is involved in CRISPR technology, which, while not a direct competitor in sequencing, competes in the broader genomics market where Illumina operates.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine is focused on gene editing technology, representing a competitive force in the genomics industry by offering alternative approaches to genetic analysis and modification.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is engaged in gene-based medicine, indirectly competing with Illumina by advancing the application of genomics in therapeutic development.

About

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Show more...
CEO
Jacob Thaysen
Employees
8650
Country
United States
ISIN
US4523271090
WKN
000927079

Listings

MU
DE
ILU.MU
LSE
GB
0J8Z.LSE
STU
DE
ILU.STU
MI
IT
1ILMN.MI

0 Comments

Share your thoughts

FAQ

What is Illumina stock price today?▼
The current price of ILMN is $218.22 USD — it has decreased by -1.55% in the past 24 hours. Watch Illumina stock price performance more closely on the chart.
What is Illumina stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Illumina stocks are traded under the ticker ILMN.
Is Illumina stock price growing?▼
ILMN stock has risen by +1.22% compared to the previous week, the month change is a +7.49% rise, over the last year Illumina has showed a +123.4% increase.
What is Illumina market cap?▼
Today Illumina has the market capitalization of 32.95B
When is the next Illumina earnings date?▼
Illumina is going to release the next earnings report on October 29, 2026.
What were Illumina earnings last quarter?▼
ILMN earnings for the last quarter are 1.31 USD per share, whereas the estimation was 1.23 USD resulting in a +6.82% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Illumina revenue for the last year?▼
Illumina revenue for the last year amounts to 4.34B USD.
What is Illumina net income for the last year?▼
ILMN net income for the last year is 850M USD.
How many employees does Illumina have?▼
As of September 04, 2026, the company has 8,650 employees.
In which sector is Illumina located?▼
Illumina operates in the Health & Wellness sector.
When did Illumina complete a stock split?▼
The last stock split for Illumina was on September 23, 2008 with a ratio of 2:1.
Where is Illumina headquartered?▼
Illumina is headquartered in SAN DIEGO, United States.